FDA Approves Pacritinib for Treatment of Myelofibrosis

Pacritinib fills a treatment gap for patients with myelofibrosis and a low platelet count

Related Keywords

New York ,United States ,John Mascarenhas ,Drug Administration ,Research Foundation ,Blood Cancers ,Myeloid Disorders ,Mount Sinai Icahn School ,New York City ,